Article

Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer: a retrospective, multicenter study

2024-02-15

Abstract excerpt

<h4>Background: </h4> Epidermal growth factor receptor ( EGFR )-mutant non-small cell lung cancer (NSCLC) have higher frequency of bone metastases than those of wild type; however, the metastatic pattern and the influence on clinical outcome remains unclear. Therefore, we retrospectively analyzed the association between bone metastatic sites and the clinical efficacy of the third-generation EGFR-tyrosine kinase in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2db91217-4bdd-577d-b8d7-254c5a0eaf65
DOI: 10.21203/rs.3.rs-3890629/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer: a retrospective, multicenter studyDOI 10.21203/rs.3.rs-3890629/v1Read

Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancerSemantic proximity Read

Prognosis of different bone metastases patterns in EGFR-mutant advanced lung adenocarcinoma patientsSemantic proximity Read

Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.Semantic proximity Read

Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis.Semantic proximity Read

Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitorsSemantic proximity Read

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasisSemantic proximity Read

Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.Semantic proximity Read

Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M-positive non-small cell lung cancer.Semantic proximity Read

Evaluation of the prognostic value of the new 9th edition Tumor-Node-Metastases (TNM) staging system for epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients with bone metastases.Semantic proximity Read

The number of brain metastases predicts the survival of non-small cell lung cancer patients with EGFR mutation status.Semantic proximity Read

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.Semantic proximity Read

Driver gene mutations and clinical features predict bone metastasis risk in NSCLC: a logistic regression model.Semantic proximity Read